ABLIM1 (Actin-Binding LIM Protein 1) is a cytoskeletal protein belonging to the LIM domain-containing protein family, characterized by its ability to interact with actin filaments and participate in cell structure organization, motility, and signal transduction. The LIM domain, a zinc-binding motif, facilitates protein-protein interactions, enabling ABLIM1 to serve as an adaptor molecule linking the actin cytoskeleton to signaling pathways. It is expressed in various tissues, including the nervous system, retina, and muscle, where it contributes to cellular polarity, adhesion, and mechanical stability.
Antibodies targeting ABLIM1 are essential tools for investigating its biological roles and regulatory mechanisms. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect ABLIM1 expression levels, subcellular localization, and interactions with binding partners. Research utilizing ABLIM1 antibodies has highlighted its involvement in neuronal development, photoreceptor maintenance, and cancer progression. For instance, studies suggest ABLIM1 may act as a tumor suppressor in certain cancers, while mutations or dysregulation are linked to retinal degenerative diseases. These antibodies also aid in exploring ABLIM1's role in mechanotransduction and its response to cellular stress. Commercial ABLIM1 antibodies are typically validated for specificity across human, mouse, and rat models, supporting translational research in both physiological and pathological contexts.